Log in

NASDAQ:GNMK - GenMark Diagnostics Stock Price, Forecast & News

$4.16
+0.05 (+1.22 %)
(As of 03/29/2020 02:33 PM ET)
Today's Range
$3.85
Now: $4.16
$4.28
50-Day Range
$3.49
MA: $4.48
$6.00
52-Week Range
$3.36
Now: $4.16
$8.17
Volume1.28 million shs
Average Volume4.75 million shs
Market Capitalization$252.84 million
P/E RatioN/A
Dividend YieldN/A
Beta1.47
GenMark Diagnostics, Inc., a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results. The company offers XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents that enable reference laboratories and hospitals to support a range of molecular tests with a workstation and disposable test cartridges. It also provides diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, thrombophilia risk test, a warfarin sensitivity test, and hepatitis C virus genotyping test and associated custom manufactured reagents, as well as 2C19 genotyping test. The company sells its products through direct sales and technically specialized service organization in the United States and Europe. GenMark Diagnostics, Inc. is headquartered in Carlsbad, California.
Read More
GenMark Diagnostics logo

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GNMK
CUSIPN/A
Phone760-448-4300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$88.02 million
Book Value$0.21 per share

Profitability

Net Income$-47,350,000.00

Miscellaneous

Employees477
Market Cap$252.84 million
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive GNMK News and Ratings via Email

Sign-up to receive the latest news and ratings for GNMK and its competitors with MarketBeat's FREE daily newsletter.


GenMark Diagnostics (NASDAQ:GNMK) Frequently Asked Questions

How has GenMark Diagnostics' stock been impacted by COVID-19 (Coronavirus)?

GenMark Diagnostics' stock was trading at $5.42 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, GNMK shares have decreased by 23.2% and is now trading at $4.16. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of GenMark Diagnostics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GenMark Diagnostics in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for GenMark Diagnostics.

When is GenMark Diagnostics' next earnings date?

GenMark Diagnostics is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for GenMark Diagnostics.

How were GenMark Diagnostics' earnings last quarter?

GenMark Diagnostics, Inc (NASDAQ:GNMK) posted its quarterly earnings data on Monday, March, 2nd. The medical equipment provider reported ($0.17) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.16) by $0.01. The medical equipment provider earned $27.20 million during the quarter, compared to analyst estimates of $27.13 million. GenMark Diagnostics had a negative return on equity of 315.97% and a negative net margin of 53.79%. View GenMark Diagnostics' earnings history.

What guidance has GenMark Diagnostics issued on next quarter's earnings?

GenMark Diagnostics issued an update on its FY 2020 After-Hours earnings guidance on Monday, March, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $100-110 million, compared to the consensus revenue estimate of $110.21 million.

What price target have analysts set for GNMK?

4 Wall Street analysts have issued 1 year price targets for GenMark Diagnostics' stock. Their forecasts range from $7.00 to $11.00. On average, they anticipate GenMark Diagnostics' stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 116.3% from the stock's current price. View analysts' price targets for GenMark Diagnostics.

What are Wall Street analysts saying about GenMark Diagnostics stock?

Here are some recent quotes from research analysts about GenMark Diagnostics stock:
  • 1. According to Zacks Investment Research, "GenMark Diagnostics, Inc. is a molecular diagnostics company focused on developing and commercializing its proprietary eSensor(R) detection technology. The eSensor® XT-8 system is the second generation in GenMark Dx's eSensor® platform, utilizing electrochemical detection technology to detect nucleic acids on a microarray. The XT-8 System enables multiplex detection of DNA and RNA targets. The Company has developed four diagnostic tests for use with its XT-8 System. Its Cystic Fibrosis Genotyping Test, which detects pre-conception risks of cystic fibrosis, and its Warfarin Sensitivity Test, which determines an individual's ability to metabolize the oral anticoagulant warfarin, have received FDA clearance. It has also developed a Respiratory Viral Panel Test, which detects the presence of major respiratory viruses, and a Thrombosis Risk Test, which detects an individual's increased risk of blood clots. GenMark Diagnostics, Inc. is based in Pasadena, California. " (3/4/2020)
  • 2. Canaccord Genuity analysts commented, "We are positive on the hire of the role of SVP of Sales, adding to the company’s management team. GenMark is well positioned to execute this year as the sales force now has the new trio" of blood culture ID panels to sell. We reiterate our BUY rating and $10 price target. Q1 was a slight beat – impressive given tough Y/Y comp. Q1 revs of $21.5M (+4% Y/ Y) beat our $20.7M (flat $20.9M, which we view as solid particularly given a very difficult comp due to last year’s record influenza season. GNMK placed 39 net ePlex instruments, above our 34E. LPS of ($0.21) matched us and was in line with Street’s ($0.20). OPEX of $16.8M (+12% Y/Y) was consistent with our $16.2M. Reiterates 2019 revenue/placement guide." (5/1/2019)

Has GenMark Diagnostics been receiving favorable news coverage?

News articles about GNMK stock have been trending extremely negative on Sunday, according to InfoTrie Sentiment. The research firm rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. GenMark Diagnostics earned a news sentiment score of -4.0 on InfoTrie's scale. They also assigned media stories about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutGenMark Diagnostics.

Are investors shorting GenMark Diagnostics?

GenMark Diagnostics saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 2,757,000 shares, an increase of 42.8% from the February 27th total of 1,930,000 shares. Based on an average daily trading volume, of 5,008,600 shares, the days-to-cover ratio is currently 0.6 days. Currently, 5.0% of the shares of the stock are sold short. View GenMark Diagnostics' Current Options Chain.

Who are some of GenMark Diagnostics' key competitors?

What other stocks do shareholders of GenMark Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GenMark Diagnostics investors own include Inovio Pharmaceuticals (INO), Opko Health (OPK), T2 Biosystems (TTOO), Co-Diagnostics (CODX), Amicus Therapeutics (FOLD), Immunomedics (IMMU), Rigel Pharmaceuticals (RIGL), NovaBay Pharmaceuticals (NBY), Biocept (BIOC) and Gilead Sciences (GILD).

Who are GenMark Diagnostics' key executives?

GenMark Diagnostics' management team includes the following people:
  • Mr. Hany Massarany, CEO, Pres & Director (Age 58)
  • Mr. Scott Mendel, Chief Operating Officer (Age 52)
  • Mr. Michael Gleeson, Sr. VP of Corp. Accounts (Age 44)
  • Mr. John Frederick Ek, Chief Financial Officer (Age 43)
  • Mr. Eric Stier, Sr. VP, Gen. Counsel & Sec. (Age 43)

What is GenMark Diagnostics' stock symbol?

GenMark Diagnostics trades on the NASDAQ under the ticker symbol "GNMK."

Who are GenMark Diagnostics' major shareholders?

GenMark Diagnostics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (14.99%), Cadian Capital Management LP (9.50%), Bank of America Corp DE (3.61%), State Street Corp (1.89%), Penn Capital Management Co. Inc. (1.68%) and Needham Investment Management LLC (1.37%). Company insiders that own GenMark Diagnostics stock include Brian Andrew Mitchell, Eric Stier, Hany Massarany, James B Mcnally, Jennifer Anne Williams, John Frederick Ek, Kevin C Oboyle, Michael Gleeson, Michael Kagnoff, Sarah Hollis Winkler, Scott Mendel and Tyler Jensen. View institutional ownership trends for GenMark Diagnostics.

Which institutional investors are selling GenMark Diagnostics stock?

GNMK stock was sold by a variety of institutional investors in the last quarter, including Cadian Capital Management LP, AQR Capital Management LLC, Oxford Asset Management LLP, Goldman Sachs Group Inc., Panagora Asset Management Inc., TD Asset Management Inc., Blair William & Co. IL, and Man Group plc. Company insiders that have sold GenMark Diagnostics company stock in the last year include Brian Andrew Mitchell, Eric Stier, Hany Massarany, James B Mcnally, John Frederick Ek, Kevin C Oboyle, Michael Gleeson, Sarah Hollis Winkler, Scott Mendel, and Tyler Jensen. View insider buying and selling activity for GenMark Diagnostics.

Which institutional investors are buying GenMark Diagnostics stock?

GNMK stock was bought by a variety of institutional investors in the last quarter, including Needham Investment Management LLC, Bank of America Corp DE, Parkman Healthcare Partners LLC, Point72 Asset Management L.P., Penn Capital Management Co. Inc., Granite Investment Partners LLC, Jacobs Levy Equity Management Inc., and Renaissance Technologies LLC. Company insiders that have bought GenMark Diagnostics stock in the last two years include Kevin C Oboyle, and Michael Kagnoff. View insider buying and selling activity for GenMark Diagnostics.

How do I buy shares of GenMark Diagnostics?

Shares of GNMK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is GenMark Diagnostics' stock price today?

One share of GNMK stock can currently be purchased for approximately $4.16.

How big of a company is GenMark Diagnostics?

GenMark Diagnostics has a market capitalization of $252.84 million and generates $88.02 million in revenue each year. The medical equipment provider earns $-47,350,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis. GenMark Diagnostics employs 477 workers across the globe. View additional information about GenMark Diagnostics.

What is GenMark Diagnostics' official website?

The official website for GenMark Diagnostics is http://www.genmarkdx.com/.

How can I contact GenMark Diagnostics?

GenMark Diagnostics' mailing address is 5964 LA PLACE COURT, CARLSBAD CA, 92008. The medical equipment provider can be reached via phone at 760-448-4300 or via email at [email protected]


MarketBeat Community Rating for GenMark Diagnostics (NASDAQ GNMK)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  531 (Vote Outperform)
Underperform Votes:  304 (Vote Underperform)
Total Votes:  835
MarketBeat's community ratings are surveys of what our community members think about GenMark Diagnostics and other stocks. Vote "Outperform" if you believe GNMK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNMK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Featured Article: Capital Gains Distribution

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel